



Certification of Mailing or Facsimile Transmission  
I hereby certify that I have reasonable basis to expect that, on the date shown below, this correspondence is being submitted as indicated below:  
[X] mailed or deposited with the United States Postal Service with sufficient postage as a first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

Andrew J. Hagerty 44.141  
Name Registration No (if applicable)  
Signature  
9/7/05 Date

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/627,533  
Applicant(s) : Donald Lynn Bissett  
Filed : July 25, 2003  
Title : Regulation of Mammalian Keratinous Tissue  
Using N-Acyl Amino Acid Compositions  
TC/A.U. : 1615  
Examiner :  
Conf. No. : 2912  
Docket No. : 9332  
Customer No. : 27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [ ] 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or

within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☒ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case).** This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).


**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

[X] In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed.

☐ Additional information is attached.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Andrew J. Hagerty

Typed or printed name

Registration No. 44,141

(513) 626-0051

Date: 9/7/05

**Customer No. 27752**

(IDS.doc) (Last Revised 4/11/2005)

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p> <p style="text-align: center;">SHEET 1 of 2</p>	<p style="text-align: center;"><b>COMPLETE IF KNOWN</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td>10/627,533</td> </tr> <tr> <td>Confirmation Number</td> <td>2912</td> </tr> <tr> <td>Filing Date</td> <td>July 25, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Donald Lynn Bissett</td> </tr> <tr> <td>Group Art Unit</td> <td>1615</td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>9332</td> </tr> </table>	Application Number	10/627,533	Confirmation Number	2912	Filing Date	July 25, 2003	First Named Inventor	Donald Lynn Bissett	Group Art Unit	1615	Examiner Name		Attorney Docket Number	9332
Application Number	10/627,533														
Confirmation Number	2912														
Filing Date	July 25, 2003														
First Named Inventor	Donald Lynn Bissett														
Group Art Unit	1615														
Examiner Name															
Attorney Docket Number	9332														

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-5,833,998 A	11-10-1998	Biedermann et al.	
	2	US-5,980,921 A	11-09-1999	Biedermann et al.	
	3	US-5,939,082 A	08-17-1999	Oblong et al.	
	4	US-6,159,485	12-12-2000	Yu et al.	
	5	US-6,217,888 B1	04-17-2001	Oblong et al.	
	6	US-6,238,678 B1	05-29-2001	Oblong et al.	
	7	US-6,524,593	02-25-2003	Yu et al.	
	8	US-2003/198656	10-23-2003	Yu et al.	
	9	US-2003/229141	12-11-2003	Yu et al.	
	10	US-2005/013784	01-20-2005	Triff et al.	

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	11	EP-0328099 A	08-16-1989	Pelliccione		
	12	JP-73312281 A	12-19-1995	Keigo et al.		XX
	13	WO 97/17060 A1	05-15-1997	Beidermann et al.		
	14	WO 97/39733 A1	10-30-1997	Oblong et al.		
	15	WO 97/39734 A1	10-30-1997	Oblong et al.		
	16	WO 00/40217 A1	07-13-2000	Yu et al.		
	17	WO 02/062312 A1	08-15-2002	Trigg et al.		
EXAMINER			DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 11/5/2004)

Please type a plus sign (+) inside this box → [+]

PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)  SHEET 2 of 2	COMPLETE IF KNOWN	
	Application Number	10/627,533
	Confirmation Number	2912
	Filing Date	July 25, 2003
	First Named Inventor	Donald Lynn Bissett
	Group Art Unit	1615
	Examiner Name	
Attorney Docket Number	9332	

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	18	ANONYMOUS: "Sepiwhite MSH" Research Disclosure, October 2002 (2002-10), vol. 462, no. 21, Kenneth Mason Publications, Hampshire, GB. XP007131318, ISSN: 0374-4353.	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**